Can Big Pharma Save Biotech Investors?
Executive Summary
Want to know how bad off small biotechs are these days? Investment bankers are so desperate to unload companies, they've taken to calling on corporate development departments with lists of "wounded animals" - those companies with just a few months of cash remaining, according to a business development head at a big pharmaceutical company
You may also be interested in...
Hit By U.S. Economic Tremors, Collapse In Biologics Business, WuXi PharmaTech Posts Massive Loss For 2008, American Unit AppTec Deeply Devalued
BEIJING - Battered in succession by the unstable U.S. economy, faltering biologics customers and mounting losses by American subsidiary AppTec Laboratory Services, WuXi PharmTech reported a net loss of more than $60 million for 2008
Merck Continues Looking For The “Right” Biotech Buying Opportunity
Speaking at a Goldman Sachs investor conference, CEO Clark discusses Merck’s plans in biotech.
Merck Continues Looking For The “Right” Biotech Buying Opportunity
Speaking at a Goldman Sachs investor conference, CEO Clark discusses Merck’s plans in biotech.